Cleary-Led GSK Completes $1.4B Asthma Drug Biz Buyout
GSK said Thursday that it has finalized the purchase of asthma drug developer Aiolos Bio Inc. for up to $1.4 billion, as the U.K. pharmaceuticals giant adds a potentially revolutionary respiratory...To view the full article, register now.
Already a subscriber? Click here to view full article